SCHEMBL859703

SCHEMBL859703

C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)C([C@H](C)/C=C/[C@@H](C)C(C)(C)O)CC[C@@H]23)C[C@H]1O

nearest known ligand 0.73

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ VDR P11473 10/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2609511 1.00 VDR (0.73) VDR
SCHEMBL2609785 1.00 VDR (0.73) VDR
SCHEMBL15371108 1.00 VDR (0.73) VDR
SCHEMBL14647794 1.00 VDR (0.73) VDR
SCHEMBL9009975 1.00 VDR (0.73) VDR
SCHEMBL15371112 1.00 VDR (0.73) VDR
SCHEMBL13759538 1.00 VDR (0.73) VDR
SCHEMBL14494338 1.00 VDR (0.73) VDR
SCHEMBL14494340 0.94 VDR (0.73) VDR
SCHEMBL13899800 0.94 VDR (0.73) VDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170326159-A1 METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID WISCONSIN ALUMNI RES FOUND (US) 2017-11-16 — — US disclosed
US-20170326159-A1 METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID WISCONSIN ALUMNI RES FOUND (US) 2017-11-16 — — US disclosed
EP-2101727-B1 COMPOSITIONS FOR USE TO TOPICALLY TREAT ACNE BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID WISCONSIN ALUMNI RES FOUND (US) 2017-11-08 — — EP disclosed
US-20160235770-A1 METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID WISCONSIN ALUMNI RESEARCH FOUNDATION 2016-08-18 — — US disclosed
US-20160235770-A1 METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID WISCONSIN ALUMNI RESEARCH FOUNDATION 2016-08-18 — — US disclosed
US-9339509-B2 Methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin D analog with or without a retinoid WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2016-05-17 — — US disclosed
US-9339509-B2 Methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin D analog with or without a retinoid WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2016-05-17 — — US disclosed
US-20140018332-A1 METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-01-16 — — US disclosed
US-20140018332-A1 METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-01-16 — — US disclosed
US-8404667-B2 2-methylene-19-nor-20(S)-1 alpha -hydroxy-bishomopregnacalciferol; 13-cis-retinoic acid activator; acne, psoriasis, ichthyosis, photoaging, photodamaged skin, skin cancer WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2013-03-26 — — US disclosed
US-8404667-B2 2-methylene-19-nor-20(S)-1 alpha -hydroxy-bishomopregnacalciferol; 13-cis-retinoic acid activator; acne, psoriasis, ichthyosis, photoaging, photodamaged skin, skin cancer WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2013-03-26 — — US disclosed
US-8143238-B2 Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin D compound WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-03-27 — — US disclosed
US-20110195941-A1 Methods of Use To Orally and Topically Treat Acne and Other Skin Conditions By Administering a 19-NOR Containing Vitamin D Analog With or Without a Retinoid WISCONSIN ALUMNI RESEARCH FOUNDATION 2011-08-11 — — US disclosed
US-20110195941-A1 Methods of Use To Orally and Topically Treat Acne and Other Skin Conditions By Administering a 19-NOR Containing Vitamin D Analog With or Without a Retinoid WISCONSIN ALUMNI RESEARCH FOUNDATION 2011-08-11 — — US disclosed
US-20090227545-A1 METHODS OF INCREASING EPIDERMAL SKIN THICKNESS BY TOPICAL ADMINISTRATION OF A 19-NOR CONTAINING VITAMIN D COMPOUND WISCONSIN ALUMNI RESEARCH FOUNDATION 2009-09-10 — — US disclosed
US-20080261925-A1 COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID WISCONSIN ALUMNI RESEARCH FOUNDATION 2008-10-23 — — US disclosed
US-20080261925-A1 COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID WISCONSIN ALUMNI RESEARCH FOUNDATION 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261925-A1 COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID CYP2R1, CYP24A1, VDR VDR 3/4885
US-20170326159-A1 METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID CYP24A1, CYP2R1, VDR VDR 3/4885
US-20140018332-A1 METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID CYP24A1, CYP2R1, VDR VDR 3/4885
US-20110195941-A1 Methods of Use To Orally and Topically Treat Acne and Other Skin Conditions By Administering a 19-NOR Containing Vitamin D Analog With or Without a Retinoid CYP24A1, CYP2R1, VDR VDR 3/4885
US-20160235770-A1 METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID CYP24A1, CYP2R1, VDR VDR 3/4885
US-20090227545-A1 METHODS OF INCREASING EPIDERMAL SKIN THICKNESS BY TOPICAL ADMINISTRATION OF A 19-NOR CONTAINING VITAMIN D COMPOUND CYP24A1, CYP2R1, VDR VDR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback